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Aim: Coats plus syndrome (CP) is a rare autosomal recessive disorder, characterised 
by retinal telangiectasia exudates (Coats disease), leukodystrophy, distinctive intrac-
ranial calcification and cysts, as well as extra- neurological features including abnor-
mal vasculature of the gastrointestinal tract, portal hypertension and osteopenia with a 
tendency to fractures. CP most frequently occurs due to loss- of- function mutations in 
CTC1. The encoded protein CTC1 constitutes part of the CST (CTC1- STN1- TEN1) 
complex, and three patients have been described with CP due to biallelic mutations 
in STN1. Together with the identification of homozygosity for a specific loss- of- 
function mutation in POT1 in a sibling pair, these observations highlight a defect in 
the maintenance of telomere integrity as the cause of CP, although the precise mecha-
nism leading to the micro- vasculopathy seen at a pathological level remains unclear. 
Here, we present the investigation of a fourth child who presented to us with retinal 
exudates, intracranial calcifications and developmental delay, in keeping with a diag-
nosis of CP, and later went on to develop pancytopenia and gastrointestinal bleeding. 
Genome sequencing revealed compound heterozygous variants in STN1 as the likely 
genetic cause of CP in this present case.
Methods: We assessed the phenotype to be CP and undertook targeted sequencing.
Results: Whilst sequencing of CTC1 and POT1 was normal, we identified novel 
compound heterozygous variants in STN1 (previous gene symbol OBFC1): one 
loss- of- function– – c.894dup (p.(Asp299Argfs*58)); and one missense– – c.707T>C 
(p.(Leu236Pro)).
Conclusion: Given the clinical phenotype and identified variants we suggest that this 
is only the fourth patient reported to date with CP due to mutations in STN1.
K E Y W O R D S
coats plus, leukodystrophy, stn1
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1 |  INTRODUCTION
Coats plus (CP) is a pleiotropic disorder affecting the brain, 
bone and gastrointestinal tract, with retinal telangiectasia and 
exudates (Coats disease), a neuroradiological triad of cere-
bral white matter disease (leukoencephalopathy), intracranial 
calcifications and cysts (LCC) and extra- neurological man-
ifestations such as osteopenia, life- limiting gastro- intestinal 
bleeding and portal hypertension caused by the development 
of vascular ectasias in the stomach/small intestine and liver 
fibrosis (Crow et al., 2004; Kapuria et al., 2019; Tolmie et al., 
1988).
CP has an overlapping phenotype with LCC (also known 
as Labrune syndrome) which is indistinguishable from CP in 
terms of the associated neuroradiology, but does not include 
the extra- neurological manifestations of CP (Labrune et al., 
1996). Of note, LCC is an apparently genetically homoge-
neous disorder due to mutations in SNORD118 (Jenkinson 
et al., 2016). Some patients with CP display hair and bone 
marrow failure– – resembling the phenotype of other telo-
meropathies, including dyskeratosis congenita, Hoyeraal– 
Hreidarsson syndrome and Revesz syndrome (Keller et al., 
2012).
CP has been associated with mutations in any of CTC1 
(Anderson et al., 2012; Polvi et al., 2012), POT1 (Takai 
et al., 2016) and, in three cases, STN1 (Simon et al., 2016; 
Passi et al., 2020). The identification of biallelic mu-
tations in CTC1 in individuals with CP has focussed at-
tention on the CST (CTC1- STN1- TEN1) complex as a 
cause of human disease. This conserved trimeric complex 
has three recognised functions; binding the telomeric G- 
strand, promoting synthesis of the C- strand and inhibiting 
telomerase- mediated telomere elongation. It is thought 
that disruption of the CST complex affects telomere length 
and telomeric C- strand synthesis, leading to elongated 3’ 
overhangs (Stewart et al., 2012). This means that the role 
of telomeres as nucleoprotein complexes in the protection 
of chromosome ends from degradation, activation of the 
DNA damage response and end- to- end fusion are compro-
mised. The principal role of STN1 is to interact and stim-
ulate the activity of DNA polymerase a- primase, the only 
enzyme known to initiate DNA replication in eukaryotic 
cells (Stewart et al., 2012). Functional studies have shown 
that stable knockdown of STN1 increases the incidence of 
anaphase bridges and multi- telomeric signals, indicating 
genomic and telomeric instability (Goulian et al., 1990).
2 |  CASE STUDY
The proband was a 9- year- old Caucasian male. Concerns 
first arose due to intrauterine growth restriction on a 20- 
week scan and at 27 weeks gestation his mother underwent 
an emergency Caesarean section because of oligohydram-
nios. He was born weighing 600 g, required ventilation for 
2 weeks and remained hospitalised for 3 months thereaf-
ter, during which time he was naso- gastrically and subse-
quently percutaneous endoscopic gastrostomy (PEG) fed. 
At the age of 30 weeks he was considered to have features 
of stage 3 retinopathy of prematurity, which was treated 
with laser therapy in both eyes. He developed conjugated 
hyperbilirubinaemia, attributed to his prematurity, which 
cleared after a few weeks. Abdominal ultrasound showed 
mild hepatomegaly.
His developmental milestones were at the upper end of the 
normal range, lifting his head at age 3 months and walking 
with support at 15 months of age after his expected delivery 
date. He had delayed speech acquisition. Cranial MRI at the 
age of 3 years revealed asymmetric white matter disease par-
ticularly involving the right occipital and parietal lobes, with 
signal change/swelling in the pons and dense calcifications 
(Figure 1). These features were in keeping with the radiolog-
ical triad of both CP and LCC. Other considerations, such as 
infection and metabolic causes for the patient's symptoms, 
were excluded.
His height and weight followed the 0.4th centile, with 
a head circumference 3.5SD below the mean. At age of 
5 years he suffered a vitreous haemorrhage in the left eye 
requiring vitrectomy. At 6  years of age abdominal ultra-
sound revealed hepatosplenomegaly with elevated trans-
aminases and no cholestasis. Liver histology showed intact 
lobular architecture without fibrosis, but small portal 
tracts lacking biliary structures. Full blood count revealed 
chronic thrombocytopenia and pancytopenia, with a white 
blood cell count of 2.1 thousands/μL, red blood cell count 
of 2.7 thousands/μL, haemoglobin of 9.7 g/dL and platelet 
count of 35 × 109/L. Furthermore, bone marrow aspirate 
and trephine revealed hypocellularity, with a reduction in 
the myeloid lineage.
By this time his neurological status had deteriorated, 
subsequently affecting his speech and with emerging dys-
tonic posturing of the right leg / arm. Cerebral MRI scan 
showed progression of areas of focal intensity including 
the left parietal and occipital lobes, along with volume 
loss of the thalami and brainstem (Figure 1). He experi-
enced episodes of haematemesis. Aged 8 years, esophago- 
gastro- duodenoscopy revealed grade 2– 3 esophageal 
varices requiring esophageal band ligation (EBL). He was 
enrolled onto a secondary prophylaxis programme for his 
portal hypertension (PHT). Proctoscopy was normal. No 
telangiectasia- like lesions were identified in the examined 
GI track. His liver ultrasound and Fibroscan showed evolu-
tion of liver disease, with features of liver fibrosis and hy-
persplenism. The oesophageal varices responded to EBL. 
Suspected low volume non- variceal GI bleeding was man-
aged with tranexamic acid.
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Unfortunately, his haemoglobin continued to drop to 
8.8  g/dL and liver ultrasound showed marked increase in 
ascites with an increase in splenomegaly from 13.8  cm to 
22.0  cm. Following a large rectal bleed and intolerance of 
feeds, he was managed palliatively, and died peacefully at age 
9. Liver failure and gastrointestinal bleeding were cited as the 
main cause of death (Table 1).
3 |  GENETIC EVALUATION
Given the CP phenotype, Sanger sequencing of CTC1 
was undertaken, but no pathological variants were iden-
tified. POT1 and SNORD118 were also examined and 
sequences found to be wild type. In contrast, sequencing 
of STN1 (previous gene symbol OBFC1) identified two 
F I G U R E  1  Neuroimaging of patient. CT images of patient aged 3 years demonstrating pontine (a) and cerebral white matter/thalamic (b) 
calcification. T2- weighted axial MRI images of patient aged 3 years showing focal areas of increased intensity of the thalami with calcification 
artefact (c) and right>left white matter (c,d,e). T2- weighted axial MRI images of patient aged 6 years showing further development of the focal 
areas of increased intensity on T2- weighted axial images of the pons with calcification artefact (f) and white matter bilaterally (g,h)
T A B L E  1  Comparison of clinical features of previously documented cases with STN1 mutation and the present case
Features Patient 1 Patient 2 Patient 3 Present study
Origin Palestine Palestine Indian United Kingdom
Gender Female Male Female Male
Age at presentation 12 years 19 years 15 days 3 years
IUGR/growth 
retardation
Yes Yes Yes Yes
GI bleed Yes Yes Yes Yes
Hepatic dysfunction Yes Yes — Yes
CNS Dystonia, ataxia — Dystonia Dystonia
Eye — Retinal telangiectasia Retinal lesions Retinal lesions
Haematological 
abnormality
Pancytopenia Pancytopenia Pancytopenia Pancytopenia








Died at 9 years due to 
uncontrollable gastrointestinal 
bleeding and liver failure
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rare variants; c.707T>C, p.(Leu236Pro) and c.894dup, 
p.(Asp299Argfs*58) in exons 7 and 9, respectively 
(Figure 2) – – DECIPHER reference number 283482 (Firth 
et al., 2009; Figure 3 and 4).
Parental testing confirmed that the variants were bial-
lelic. Of note, the p.(Leu236Pro) is not recorded in more 
than 250,000 control alleles on gnomAD, whilst the p.(As-
p299Argfs*58) has been observed only once in 251,430 
F I G U R E  2  Sanger sequencing. c.707T>C variant with amino acid substitution and c.894dup variant with sequence change downstream
F I G U R E  3  Schematic diagram of variants on STN1 protein domain
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alleles on the same control database. The c.894dup vari-
ant is predicted to create a shift in the reading frame, end-
ing in a premature stop codon 58 positions downstream. 
The c.707T>C variant alters an amino acid within the C- 
terminal CST complex STN1 domain and is predicted as 
damaging by SIFT and Polyphen2.
All genetic investigations were undertaken with con-
sent, and with appropriate ethic permissions (Leeds- west 
Multicentre Research Ethics Committee: REC reference: 10/
H1307/2; IRAS project ID: 62971).
4 |  DISCUSSION
This boy had a long period prior to accurate molecular diag-
nosis, during which he developed severe multisystem disease. 
Coats Plus is a rare, severe, autosomal recessive disorder 
characterised by a relatively stereotyped set of features: leu-
kodystrophy, calcifications and cysts; retinal telangiectasia/
exudates (i.e. Coats disease); and evolving gastrointestinal 
involvement including hepatic fibrosis, oesophageal varices 
and hepatosplenomegaly. Bone marrow failure can be pre-
sent in some cases. GI telangiectasis and osteopenia, two 
of the key features of CP, were not present in this child, re- 
emphasising the variability in presentations with mutations 
in CST components. The major cause of CP is mutations 
in CTC1, with a single family so- far reported harbouring a 
mutation in POT1. Sequencing of both of these genes was 
normal in our patient. Despite this, the clinical picture made 
any diagnosis other than CP highly unlikely. The diagno-
sis of CP was effectively confirmed with the identification 
of biallelic rare variants in STN1. The only other STN1- CP 
cases reported to date are two unrelated patients, each born 
to consanguineous Palestinian parents, found to harbour 
homozygous STN1 variants; c.404G>C; p.(Arg135Thr), 
and c.469G>T; p.(Asp157Tyr), in exons 5 and 6 of STN1, 
respectively (Simon et al., 2016); and an Indian child with 
c.397C>T (p.Arg133*) and c.985G>C (p.Ala329Pro) in 
exons 5 and 10, respectively (Passi et al., 2020). Further bio-
logical analysis such as telomere length by flow- FISH would 
be important in supporting our claim.
In summary, we report novel compound heterozygous 
STN1 variants associated with Coats Plus, thereby expanding 
the associated molecular spectrum and emphasising the dev-
astating nature of this multi- system disease.
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